- ORGANIZED BY
- SPONSORS
- SUPPORTERS
- MEDIA SPONSORS
- PRESS OFFICE
- CONFERENCE EXPERIENCE SPONSOR
Thursday, April 19, 2018
In Greece as in the EU, cancer is expected to become the leading cause of death over the next decade. The pace of innovation in oncology is tremendous and unprecedented: newly approved drugs abound; precision oncology and immunotherapy are gradually becoming a reality; and patients are having access to an increasing number of treatment options that help them live longer with better quality of life. In an effort to approach more effective treatments for cancer and rare diseases both the research-scientific community and pharmaceutical companies have also turned their attention to the field of personalized medicine. Personalized medicine promises to significantly increase the drugs’ effectiveness while reducing the side effects of treatment, thus improving patients’ quality of life during their treatment.
On the other hand, in today’s challenging economic climate, many governments are targeting their health care systems to increase efficiency and curtail expenditure in the context of broader austerity programs. Amidst all this, the biggest challenge moving ahead is to build and ensure a robust health systems response for cancer control. A national cancer plan is also instrumental and remains critical in optimizing access and treatment for patients, getting the right balance between the cost of innovation and sustainability for continued affordable access to innovative cancer treatments.
The aim of the conference is to explore opportunities for greater multi-stakeholder cooperation and a more integrated approach to cancer care as key drivers to deliver sustainable and high-value care for patients. Best practices at a national and international level will contribute to the dialogue aiming at significantly improving cancer patient outcomes and reducing the financial burden targeted to this disease.